Research Knowledge Hub
Comprehensive educational resources for laboratory protocols, verification methodologies, and research safety standards.
Knowledge areas
Scientific Studies Database
Browse peer-reviewed research on peptide compounds with direct links to published literature.
Browse StudiesFrequently Asked Questions
Quick answers to the most common beginner questions about research peptides.
Browse FAQPeptides 1x1
Foundational knowledge about peptides – the essential basics every researcher should know. Start here to build a solid understanding of peptide science.
Blog
Articles, insights, and guides about peptide research, industry trends, and best practices.
News & Updates
Latest research findings, study results, and industry developments in the peptide space.
All Articles
CBP Seizes 5,000+ Mislabeled Peptide Shipments at Cincinnati: What Makes an Import Seizable
CBP reported seizing about 5,000 China-origin peptide shipments hidden in 300+ master cartons (Dec 2025-Mar 2026). Here is why customs seizes imports and what makes one seizable.
MOTS-c Mechanism, Corrected: A 2026 Study Reframes the Mitochondrial Peptide's Action
A January 2026 study reframes MOTS-c's mechanism: the 12S rRNA-encoded peptide tunes existing mitochondrial efficiency via PGC-1a/AMPK, not biogenesis.
The Next Tranche: Five More Peptides Headed to a Second FDA PCAC Review by February 2027
After the July 2026 docket of seven peptides, the FDA scheduled a second PCAC review before the end of February 2027 for five more 503A bulk substances.
The Janoshik Data Breach: What a 2026 Testing-Lab Compromise Means for COA Trust
In February 2026, Janoshik Analytical disclosed a data breach exposing customer order and shipping data. What was reportedly exposed, the ISO 17025 question, and what it means for COA trust.
From Warning Letters to Indictments: The 2026 Shift to Criminal Peptide Enforcement
A Utah osteopathic physician was indicted in early April 2026 over allegedly misbranded China-sourced peptides – a reported shift from FDA warning letters toward criminal prosecution.
Free Base vs. Acetate: Why the FDA Reviews Each Peptide Salt Form Separately at the July 2026 PCAC
The FDA's July 2026 PCAC lists peptides twice – free base and acetate – as distinct 503A nominations. Here is how salt form changes identity and COA reading.
Beyond Janoshik: The 2026 Third-Party Peptide-Testing Lab Landscape
In 2026, independent peptide labs (Janoshik, Testides, ACS, MZ Biolabs, Colmaric) differ on methods and ISO 17025 accreditation. Compare the landscape here.
The 2025-2026 Research-Peptide Vendor Shutdown Wave: Who Closed and What It Signals
Trade coverage counts at least eight gray-market research-peptide vendors closing in 2025-2026, including Science.bio and Peptide Sciences, amid FDA, CBP and litigation pressure.
The EMA Synthetic-Peptide Manufacturing Guideline Took Effect 1 June 2026: What It Standardizes
The EMA synthetic-peptide guideline (effective 1 June 2026) standardizes impurity thresholds, nitrosamine risk assessment, and orthogonal characterization for peptide quality data.
"Research Use Only" Is Now an FDA Enforcement Target: The April 2026 Peptide Warning Letters
No. According to the FDA, a "Research Use Only" label does not shield a peptide vendor. In April 2026 the agency published seven warning letters citing FD&C Act 201(g)(1).
GHK-Cu Removed From the FDA Category 2 Bulks List in 2026: Copper-Peptide Chemistry & Status
GHK-Cu (copper tripeptide-1) was removed from the FDA Category 2 list in April 2026 per legal analyses. Here is what changed, what it does not mean, and the copper chemistry.
Enlicitide: The Oral Macrocyclic Peptide Aiming to Be the First Pill PCSK9 Inhibitor
Enlicitide (MK-0616) is an investigational oral macrocyclic peptide PCSK9 inhibitor. Macrocyclization enables oral bioavailability; Merck reports it is progressing toward FDA filing.
FDA Import Alert 66-41 Refreshed: DWPE and Peptide Imports in 2026
FDA Import Alert 66-41, revised 19 May 2026 per FDA's change note, authorizes detention without physical examination (DWPE) of unapproved-drug peptide imports at the border.
Elamipretide (SS-31) Becomes the First Cardiolipin-Directed Mitochondrial Drug Approved
Elamipretide (SS-31), branded FORZINITY, received FDA accelerated approval on Sept 19, 2025 as the first cardiolipin-targeting mitochondrial peptide drug, per its sponsor.
Audit Finds Hidden Structural Bias in AI Peptide-Design Models (bioRxiv, May 2026)
A May 2026 bioRxiv preprint audits 16 machine-learning peptide-activity predictors and reports fold-imbalance bias and data leakage – a data-integrity caution.
Why an Independent COA Matters: Purity Discrepancies, Endotoxin and Impurity Immunogenicity
Reported COA purity gaps, bacterial endotoxin and the immunogenic risk of peptide impurities – the analytical case for independent Certificate of Analysis review.
Seven Research Peptides Head to the FDA July 2026 Advisory Committee: A Chemical Identity Primer
Ahead of the FDA July 2026 PCAC review, a chemistry primer on BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax and Epitalon: identity, salt form and characterization.
FDA Moves to Permanently Exclude Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
The FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list while warning letters target research-peptide sellers.
Best Peptides for Muscle Growth 2026: What Research Actually Shows
Top 10 muscle-growth peptides ranked by 2026 evidence: CJC/Ipa, tesamorelin, sermorelin, IGF-1 LR3, PEG-MGF, follistatin, ACE-031, MK-677, hexarelin, GHRP-2/6.
Best Peptides for Fat Loss 2026: Evidence-Based Rankings
Top 10 fat-loss peptides ranked by 2026 clinical evidence: tirzepatide, semaglutide, retatrutide, cagrilintide, AOD-9604, CJC/Ipa, MOTS-c, more.
Ozempic Alternatives: 7 Verified Research Peptides Compared 2026
Seven Ozempic alternatives in 2026: tirzepatide, liraglutide, cagrilintide, retatrutide, survodutide, orforglipron, AOD-9604. Receptors, MW, status.
Mounjaro vs Ozempic vs Wegovy: 2026 Complete Comparison Guide
Tirzepatide (Mounjaro/Zepbound) vs semaglutide (Ozempic/Wegovy) 2026: SURMOUNT-5 head-to-head, MW, dosing, side effects, supply, GIP/GLP-1 dual action.
Ozempic vs Wegovy: Same Drug, Different Indications Explained 2026
Ozempic and Wegovy are chemically identical semaglutide. Differences are dose, indication, label, and price. 2026 supply, insurance, oral semaglutide launch.
Peptide Telehealth vs Research-Grade: Cost and Access Comparison 2026
Compare peptide telehealth platforms with research-grade reference material on cost, access, prescription requirements, and post-ban landscape.